Corcept Therapeutics (CORT) Cash from Investing Activities (2012 - 2026)

Corcept Therapeutics has disclosed Cash from Investing Activities across 15 years of filings, most recently posting $4.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $4.5 million, up 243.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.5 million (up 145.1% YoY), and the FY2025 annual result was $69.8 million, up 139.28% from the prior year.
• Cash from Investing Activities came in at $4.5 million for Q1 2026 at Corcept Therapeutics, up from -$11.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $207.5 million in Q1 2023 to a low of -$109.6 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is -$11.8 million (2025), against an average of -$7.5 million.
• Peak annual rise in Cash from Investing Activities reached 510.87% in 2023, while the deepest fall reached 2187.47% in 2023.
• Corcept Therapeutics' Cash from Investing Activities stood at -$17.2 million in 2022, then surged by 199.17% to $17.1 million in 2023, then slumped by 476.42% to -$64.4 million in 2024, then jumped by 81.6% to -$11.8 million in 2025, then soared by 138.35% to $4.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $4.5 million (Q1 2026), -$11.8 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.